Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Todos Medical Provides End of Second Quarter 2021 Corporate Update

Published

on

  •  Tollovir™ COVID-19 anti-viral scientific and clinical development progressing in Israel with plans progressing rapidly to expand into India in non-hospitalized setting
  •  Tollovid™ dietary supplement focusing on international distribution partnerships
  •  Videssa™ breast cancer and LymPro™ Alzheimer’s blood tests are being prioritized as key proprietary diagnostic programs and are the centerpiece of Nasdaq listing strategy
  •  Company to leverage Provista Diagnostics CLIA lab by focusing on sales of COVID-19 PCR and neutralizing antibody testing services to increase margin on revenues

NEW YORK, NY, and TEL AVIV, ISRAEL, June 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today provided a corporate update to the marketplace following the filing of its quarterly financials for the first quarter of 2021.

“The first half of 2021 has seen a dramatic shift in the COVID-19 marketplace in the United States,” said Gerald E. Commissiong, President & CEO of Todos Medical. “In light of the emerging Delta variant circulating widely in the US, there is now a clear need for novel COVID-19 antiviral therapies to protect the unvaccinated and those for whom authorized vaccines do not confer immunity, which includes a large portion of the elderly and those taking immune suppressants, against COVID-19 infection. The Biden administration recently underscored this need by pledging to invest $3.2 billion into research for COVID-19 antiviral therapies, similar to the US government’s investments into COVID-19 vaccines in 2020 at the beginning of the pandemic. We believe this government recognition of the need for antivirals will provide a significant tailwind for the development of our Tollovir™ antiviral that is currently undergoing a Phase 2 clinical trial in Israel with plans progressing rapidly to expand the clinical development program to India.  We are also optimistic about the interest we have seen from several potential international distribution partners for our dietary supplement Tollovid that provides immune support as a protease inhibitor. We expect to build a significant international distribution footprint in the second half of 2021 as we begin our initial roll-out of this important product.  

“As the COVID-19 pandemic remains very fluid, the US has focused its efforts on vaccination in the first half of 2021, which has largely been successful in bringing down daily COVID-19 case numbers and has given confidence to state governments to re-open economies with limited COVID-19 restrictions. We see this vaccination focus creating a significant new opportunity for our recently acquired CLIA/CAP certified lab, Provista Diagnostics.  Through Provista we are focusing our COVID-19 diagnostic testing strategy to prioritize delivering diagnostic services, including PCR and neutralizing antibody testing, thereby expanding beyond simply distributing testing supplies.  This expansion into testing services serves to diversify our business into higher margin revenue in the COVID-19 space, as well as help us to expand our business development opportunities with the labs we work with by providing reference lab testing services as we increase Provista’s automated testing capabilities. We are especially excited to begin our expansion into COVID-19 neutralizing antibody testing that receives nearly double the reimbursement vs. traditional COVID antibody testing (~$79 vs. ~42). We believe neutralizing antibody testing will become more critical to help determine robust COVID-19 immunity.”

Mr. Commissiong continued, “Going forward, the Company is concentrating its extensive investment in automated lab equipment to the benefit of Provista. We have begun working to substantially expand Provista’s lab sales team to build relationships with healthcare providers prescribing tests to patients, as well as provide reference lab testing services to CLIA labs who are looking to deprioritize internal COVID-19 testing. Due to our lab automation infrastructure and distributor pricing for our reagents, we believe that we can compete for large volume COVID-19 testing business, and we expect to see a resurgence in this testing in the fall as schools seek to re-open in classroom learning for K-12 and college-aged students who are the least likely groups to have been vaccinated, as well as among employers. We believe that the significant strides we have made at Provista will position the Company to accelerate growth into 2022 and build significant long-term value for the benefit of our stockholders.”

Tollovir™ Phase 2 Scientific and Clinical Development Programs

We are continuing to make progress with enrollment of our Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, with our TolloTest™ biomarker being used for the first time as a surrogate biomarker to monitor patient response to treatment. The recent resurgence of COVID-19 in Israel, driven by the Delta variant, has increased hospitalizations in both the vaccinated and unvaccinated, and has led to a reimposition of indoor mask mandates to help curb the spread. While the total number of hospitalized patients remains relatively low, we see the Israel program as critical to our overall clinical development strategy because the clinical investigators we are working with in Israel have tremendous international collaborators who think quite highly of the science emerging from Israel, making them willing to collaborate on broader international clinical development programs that will likely be needed for the ultimate regulatory approval of Tollovir.

As part of the ongoing scientific effort to further elucidate the mechanisms that have enabled Tollovir to achieve its very positive early clinical results, our partners at NLC Pharma identified an anti-inflammatory mechanism of action of Tollovir to complement its 3CL protease inhibiting mechanism. This dual mechanism of action helps more readily explain the significant reduction in symptoms and the biomarker C Reactive Protein (CRP) that was documented in the earliest clinical COVID-19 data sets produced in Israel, which could not be explained by a reduction in viral load alone likely caused by Tollovir’s 3CL protease inhibiting mechanism. As a result of these quite complementary 3CL protease inhibiting and anti-inflammatory mechanisms, given that we are in a race with Pfizer to get to market with the first 3CL protease inhibiting COVID-19 antiviral for which therapeutic claims could be made, we believe it is critical to rapidly expand our clinical development programs to gather additional data in multiple clinical settings to demonstrate Tollovir’s ability to help patients suffering from COVID-19.

As part of that effort, our Israel-based Principal Investigators have introduced us to physician clinical collaborators in India who work with a highly-respected local Clinical Research Organization (CRO) with extensive experience in running COVID-19 clinical trials. This CRO has near-immediate access to 6 clinical sites that have previously enrolled patients into clinical trials for hospitalized COVID-19 patients and 5 clinical sites that have previously enrolled patients into clinical trials for non-hospitalized COVID-19 patients. We believe this CRO relationship will allow for the rapid expansion of enrollment for Tollovir’s clinical data acquisition, and allow us to quickly prepare for a Phase 3 international clinical development program to support regulatory approval under Emergency Use Authorization. We are working closely with NLC Pharma to finalize the agreements needed to bring these clinical programs forward, with the expectation that we will be in a position to begin dosing patients in India in August 2021. We do not expect significant expenses to be associated with the clinical program in India at least through the completion of Phase 2 studies.

We believe that Tollovir may ultimately represent a new standard of care in the treatment and management of COVID-19 patients, and we are working diligently to make certain its clinical development execution will lead to the creation of clinical data that will be extremely valuable for regulators seeking to approve the product’s use, as well as potential partners who may become further interested in the program as additional clinical and scientific data emerges.

Tollovid™ distribution plans

We are very pleased that the Company’s dietary supplement Tollovid received FDA authorization for a new 5-day dosing regimen in April 2021. We believe this authorization underscores the emerging need in the marketplace for immune support supplements supported by strong scientific and safety data, as well as provides international regulatory authorities with a high degree of comfort of Tollovid’s safety profile. We also recently launched the website www.myTollovid.com where Tollovid can be purchased online directly from Todos Medical in the United States, creating a new distribution channel beyond The Alchemist’s Kitchen initial retail footprint for the product.

Going forward, the Company sees two critical areas of expansion in the advancement of Tollovid:

  1. International distribution partnerships in jurisdictions where high value dietary supplements are distributed by reputable pharmacies and other high-end wellness stores that can engage with consumers directly on the value and underlying science of their products; and
  2. US marketing campaign to dramatically expand awareness of Tollovid for consumers and distribution partners who are looking for products to further support immune function.

The Company is making steady progress in identifying international distribution partners for Tollovid, and we expect to begin to make announcements on this front in the third quarter of 2021. 

With regards to a significant US marketing campaign, the Company is evaluating the best path forward to utilize our resources and create demand in both the investor and consumer community for Tollovid. As part of that effort, we believe that independent funding to support sales and marketing for a Tollovid-focused entity, potentially through crowdfunding, may be the best use of the existing Tollovid commercial material and the best financing path forward in order to mitigate potential dilution of using Todos resources on a marketing campaign. The Company expects to make progress towards independent funding for Tollovid in the third quarter of 2021.

Todos Corporate Profile: Videssa™ Breast Cancer, LymPro Alzheimer’s blood tests and Revenue

As the Company engages with the investor community and NASDAQ as part of a potential listing process, it is important that we crystalize our corporate profile and begin to prioritize our resources towards the areas that will create long-term value for shareholders. For this reason, we are moving in the direction of packaging Tollovir, TolloTest, and Tollovid, three extremely exciting programs that Todos Medical has incubated as part of its push into COVID-19 at the height of the pandemic, into a separate unit of programs that will be ultimately be self-financed, spun-off, partnered and/or sold in order to create maximum shareholder return on the investment made as they make their way through their development and commercialization cycle. 

Going forward, the Company will be focused on bringing forward the crown jewel from its recent Provista Diagnostics acquisition: the Videssa Breast Cancer blood test. We believe Videssa could ultimately represent a new standard of care in certain areas for breast cancer screening, a marketplace that remains dramatically underserved both domestically in the US as well as internationally, and for which Todos Medical is extremely well positioned to disrupt. Because of the extensive peer-reviewed clinical data already published on Videssa, the next key milestone is to analytically revalidate the assay at Provista and engage with Key Opinion Leaders on the best intended use to initially launch the product based on the data we have already gathered. Our Chief Medical Advisor Dr. Jorge Leon has become much more heavily involved in the Videssa test over the last several weeks as we have been making key decisions on the corporate profile Todos is presenting to NASDAQ. He has become a very strong advocate for focusing the Company on Videssa where we can begin to generate significant clinical utility data for Videssa in the next 6-12 months and potentially significantly disrupt the $7 billion breast cancer screening market.

Additionally, the recent approval of Biogen’s Aduhelm™ amyloid beta antibody has significantly increased the value of the Company’s proprietary LymPro Alzheimer’s blood test, that has shown to extremely strong correlation data (p=0.000002) with amyloid beta PET imaging SUVR scores in preliminary studies performed by our partners at Leipzig University in Germany under the direction of Dr. Thomas Arendt. We believe that payers will require patients to undergo amyloid PET imaging prior to prescribing Aduhelm. In the effort to identify those patients who are likely to be positive for PET imaging, and mitigate the negative side effects of the radioactive materials used in the conduct of amyloid PET imaging testing for those unlikely to be amyloid positive, payers will want to pre-screen patients with minimally invasive tools that could give them a higher degree of confidence that a patient will be amyloid beta positive by PET imaging. LymPro could fill this emerging need for physicians and payers, as well as fulfill this area of need for pharmaceutical companies seeking to enrich their screening for clinical trials. Given the $250 billion marketplace for Alzheimer’s that is expected to grow rapidly as new treatment options continue to get market authorization in the US, we believe LymPro could also help drive mid-term value for Todos as progress is made.

In support of the Company’s proprietary Videssa and LymPro tests, Todos will continue to be focused on generating revenue through the sale of diagnostic tests, with a greater emphasis being placed on expanding diagnostic testing services provided to the marketplace through Provista’s CLIA/CAP certified lab due to the increased margins vs. the reagents sales business. The reason why lab services represents a much more attractive business than reagents sales is because the margins per test are 10-15x higher per test on revenues that are 4-10x higher per test than selling regents. From a financial forecasting standpoint, free cash flow generated from $10M in sales from lab sales of COVID-19 testing services would be close to $7M on the sale of 100,000-125,000 tests, whereas free cash generated from $10M in sales of reagents would be $4M on sales ~500,000 tests. As such, we see the acquisition of samples for Provista as the next natural evolution in our CLIA testing strategy in order to support the ultimate commercialization and market acceptance of our proprietary Videssa and LymPro blood tests.

Long-term, we expect Todos core TBIA artificial intelligence testing platform that currently has a CE Mark for Breast Cancer and Colon Cancer to be able to replace Videssa and LymPro, while substantially reducing our costs of goods sold (COGS), however because of the data-hungry nature of AI/machine learning in healthcare, we will be focusing TBIA for the foreseeable future on creating equivalency data to Videssa and LymPro as those products are commercialized. We believe TBIA could ultimately represent an entirely new blood testing platform that has the potential disrupt the marketplace when it has achieved the level of data necessary to overcome current AI-driven biomarker objections.

NASDAQ Listing Plans and Corporate Profile

On June 28, 2021, the Company disclosed the agenda for the Annual General Meeting of its stockholders that will be held on July 26th, 2021. As part of the agenda for the meeting, several proposals were put forward to shareholders to vote on by proxy to allow the Company to be positioned to achieve a Nasdaq listing in the third quarter of 2021, depending on market conditions. Two of the key proposals for shareholders to vote on in the proxy are an increase in authorized Ordinary Shares, as well as a reverse split of Ordinary Shares. It is important to note that under Israel law, there can only be a proportional split of issued and authorized shares, meaning that if there is a reverse split of the outstanding shares 1:10, then there must be a proportional reverse split of the authorized shares by the same 1:10 ratio.

The Company is working closely with its Nasdaq listing consultants, and as part of that process, management and the Board of Directors was given the advice that in negotiations for a potential listing with Nasdaq it is critical that the Company has stockholder authorization to execute whatever corporate actions are necessary to allow its common stock to meet the initial Nasdaq listing standards. This in no way means that the Company is required to execute a maximum reverse split to achieve those listing standards. Given that market forces in the OTC marketplace, it is important that the market is aware that the Company is able to achieve a Nasdaq listing under any circumstances in order to protect the Company and its shareholders.

Management continues to believe the Company is substantially undervalued and we see important corporate milestones being achieved in the third quarter of 2021 that will ultimately drive fundamental value, especially driven by our Tollovir clinical development program. We are excited about the path forward for Todos given the consolidation of all the Company’s programs into a focused strategy centered on our industry leading diagnostics programs that have an emerging revenue base to support their development, with the tremendous potential upside of an antiviral therapy for COVID-19 that could dramatically alter the standard of care for patients worldwide and potential applications beyond COVID-19.

The Board of Directors and management would like to thank our shareholders for their tremendous support as the Company embarks on the next exciting chapter of its progress, and we look forward to communicating with our shareholder on an ongoing basis in the weeks and months ahead as the Company achieves key milestones that will help drive it forward in its mission to help patients.

For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com.

For COVID-19 testing inquiries, please email [email protected].

About Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. 

For more information, please visit https://www.todosmedical.com/.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Corporate and Investor Contact:

Richard Galterio

Todos Medical

732-642-7770

[email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Predictive Maintenance Market worth $47.8 billion by 2029 – Exclusive Report by MarketsandMarkets™

Published

on

predictive-maintenance-market-worth-$47.8-billion-by-2029-–-exclusive-report-by-marketsandmarkets™

Real-time analysis and decision-making will be made easier by developments in AI and IoT integration, which will drive the Predictive Maintenance Market in the future. Innovation will be fueled by prognostics, industry-specific solutions, and interoperability, while Predictive Analytics as a Service (PAaaS) models will make advanced predictive maintenance skills more accessible to all.
CHICAGO, March 29, 2024 /PRNewswire/ — The Predictive Maintenance Market is estimated to grow from USD 10.6 billion in 2024 to USD 47.8 billion in 2029, at a CAGR of 35.1% during the forecast period, according to a new report by MarketsandMarkets™. The driving factors for the Predictive Maintenance Market include the widespread adoption of emerging technologies like IoT sensors and data analytics, enabling real-time monitoring of equipment health. The integration of machine learning (ML) and artificial intelligence (AI) algorithms allows for predictive analysis of potential failures, reducing downtime and optimizing asset performance. Organizations are increasingly focused on cost savings and operational efficiency, driving the need for proactive maintenance strategies to minimize unplanned downtime and maximize productivity. Additionally, regulatory requirements and the shift towards predictive analytics-driven decision-making further contribute to the growth of the Predictive Maintenance Market.

Browse in-depth TOC on “Predictive Maintenance Market”
280 – Tables 60 – Figures300 – Pages
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=8656856
Scope of the Report
Report Metrics
Details
Market size available for years
2019–2029
Base year considered
2023
Forecast period
2024–2019
Forecast units
USD Billion
Segments Covered
Component (Hardware, Solution [Solution by Deployment mode {Cloud (Public, Private, Hybrid) & On-premises}] & Services), Technology (Analytics & Data Management, Artificial Intelligence, IoT Platform, Sensors & Other Devices), Technique (Vibration Analysis, Infrared Thermography, Acoustic Monitoring, Oil Analysis, Motor Circuit Analysis, Other Techniques) Organization size (Large Enterprises, SMEs), Vertical (Energy & Utilities, Manufacturing, Automotive & Transportation, Aerospace & Defense, Construction & Mining, Healthcare, Telecommunications) and Region.
Geographies covered
North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Companies covered
IBM (US), ABB (Switzerland), Schneider Electric (France), AWS (US), Google (US), Microsoft (US), Hitachi (Japan), SAP (Germany), SAS Institute (US), Software AG (Germany), TIBCO Software (US), Altair (US), Oracle (US), Splunk (US), C3.ai (US), Emerson (US), GE (US), Honeywell (US), Siemens (Germany), PTC (US), Dingo (Australia), Uptake (US), Samotics (Netherlands), WaveScan (Singapore), Quadrical Ai (Canada), UpKeep (US), Limble (US), SenseGrow (US), Presage Insights (India), Falcon Labs (India).
By component, the services segment to account for higher CAGR during the forecast period.
The services segment plays a crucial role in the Predictive Maintenance Market, serving as a core component essential for the efficient operation of software solutions. Many companies are turning to intelligent devices, robust AI systems, and Industrial Internet of Things (IIoT) solutions to monitor the health and productivity of critical equipment, aiming to minimize costly production shutdowns. Remote monitoring of machinery and equipment has become a significant priority for organizations grappling with challenges in detecting machinery failures. The adoption of predictive maintenance services, including IoT, has become imperative to mitigate the risks and failures of machines across various industries. Within the services segment, managed and professional services are considered vital for enhancing overall process efficiency.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=8656856
By Technique, Vibration Analysis is expected to hold the largest market size for the year 2024.
Vibration analysis is a crucial technique employed primarily for high-speed rotating equipment in predictive maintenance strategies. It enables technicians to monitor the vibrations of machines using handheld analyzers or real-time sensors integrated into the equipment itself. Machines operating optimally exhibit specific vibration patterns, which can be compared against known standards. However, as components like bearings and shafts wear down or develop faults, they generate distinct vibration patterns, signaling potential issues. By continuously monitoring equipment vibrations, trained technicians can identify deviations from normal patterns and diagnose problems early on. The range of issues detectable through vibration analysis is extensive and includes misalignment, bent shafts, unbalanced components, loose mechanical parts, and motor irregularities.
By Vertical, Automotive & Transportation is projected to grow at the highest CAGR during the forecast period.
As automotive technology progresses rapidly, traditional fault detection methods are inadequate for ensuring vehicle smoothness. However, modern automobiles are equipped with various sensors, instruments, and cameras that generate diverse data. Leveraging this data, past service records, and employing AI and ML, predictive maintenance in the automotive & transportation sector emerges as a powerful solution to enhance vehicle performance and minimize downtime. The surge in intelligent technologies has spurred predictive maintenance investments in transportation, particularly accelerated by the Covid-19 crisis, where consumer preferences shifted towards individual mobility due to health and safety concerns, leading to an increased demand for cars. This demand surge, coupled with slowed new vehicle production, is driving the resurgence of the used car market. Predictive maintenance plays a crucial role in reducing the lifespan of used cars and preventing unexpected downtimes. Solutions like IBM’s monitoring for connected vehicles and collaborations between automakers and tech companies like Ford, CARUSO, and HIGH MOBILITY showcase the industry’s commitment to leveraging predictive maintenance for improved operations and customer services.
Middle East & Africa is expected to grow at the second-highest CAGR during the forecast period.
The Middle East & Africa (MEA) lacks technological development as well as primary business growth in many verticals. Slow economic growth and geopolitical conditions are the major hurdles to the growth of the Predictive Maintenance Market in the region. Moreover, it generates the majority of the revenues from natural resources. The government policy in the United Arab Emirates (UAE) is supportive of the industry with the vision to be one of the most technologically advanced nations by 2022. The proliferation of telecom and IT-enabled industry in the African countries is steering the growth of AI-based IoT companies in the region. The major reasons that are said to influence the growth of the Predictive Maintenance Market in the region are the increasing investments in data center infrastructures and the growing number of high-growth start-ups. Only a few countries, such as the UAE, Israel, and Qatar, across the region, are advancing in this market at an economical pace. The UAE, Israel, and Qatar have demonstrated a strong commitment toward the development and implementation of AI and IoT technologies.
Top Key Companies in Predictive Maintenance Market:
The major predictive maintenance hardware, solution and service providers include IBM (US), ABB (Switzerland), Schneider Electric (France), AWS (US), Google (US), Microsoft (US), Hitachi (Japan), SAP (Germany), SAS Institute (US), Software AG (Germany), TIBCO Software (US), Altair (US), Oracle (US), Splunk (US), C3.ai (US), Emerson (US), GE (US), Honeywell (US), Siemens (Germany), PTC (US), Dingo (Australia), Uptake (US), Samotics (Netherlands), WaveScan (Singapore), Quadrical Ai (Canada), UpKeep (US), Limble (US), SenseGrow (US), Presage Insights (India), Falcon Labs (India). These companies have used both organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the Predictive Maintenance Market.
Recent Developments:
In January 2024, Siemens and AWS deepened their collaboration to simplify the development and scaling of generative artificial intelligence (AI) applications for businesses across various industries and sizes. This partnership enables domain experts in fields like engineering, manufacturing, logistics, insurance, or banking to leverage advanced generative AI technology to create and enhance applications efficiently.In December 2023, ABB enhanced its ABB Ability Field Information Manager (FIM 3.0) to provide system engineers and maintenance teams with enhanced connectivity and expanded reach across the latest communication protocols.In June 2023, Qatar Airways and Google Cloud partnered to create innovative data and artificial intelligence (AI) solutions tailored for the airline industry. This collaboration will concentrate on enhancing areas like predictive maintenance, passenger experience, and cargo operations, aiming to elevate efficiency and customer satisfaction within the airline sector.In April 2023, TrendMiner launched an updated version of its predictive maintenance software, the Digital Twin Manager. This release includes enhanced support for cloud data sources from AWS and Microsoft, along with interactive search functionality, enabling users to make data-driven decisions more efficiently.In January 2023, AVEVA, a global leader in industrial software, finalized its acquisition by Schneider Electric. AVEVA’s strategic objective is to emerge as the top Software as a Service (SaaS) provider in software and industrial information, transitioning to a subscription-only business model.Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=8656856
Predictive Maintenance Market Advantages:
Through proactive equipment maintenance based on data-driven insights, the prevention of expensive unplanned downtime, and the reduction of repair costs, predictive maintenance assists organisations in cutting maintenance costs.Predictive maintenance increases equipment availability and uptime by anticipating possible equipment faults before they happen, guaranteeing continuous operations and maximising output.By locating and resolving underlying problems that may compromise the dependability and efficiency of equipment, predictive maintenance extends the life of assets and lowers the need for untimely replacements.Predictive maintenance reduces the likelihood of mishaps, injuries, and interruptions to operations brought on by malfunctioning equipment by anticipating possible equipment breakdowns.By scheduling maintenance jobs more effectively, predictive maintenance helps businesses minimise interruptions to existing operations and match maintenance duties with production schedules.Using data analytics and machine learning algorithms, predictive maintenance produces actionable insights that help with equipment investments, resource allocation, and maintenance strategy selection.Predictive maintenance ensures continuous functioning and customer satisfaction by proactively addressing equipment concerns, minimising unplanned downtime and production losses.Status-based maintenance techniques, which optimise maintenance resources and cut down on pointless inspections and repairs by triggering maintenance actions based on real-time equipment status data, are made possible by predictive maintenance.Report Objectives
To describe and forecast the Predictive Maintenance Market, in terms of value,by component, technology, technique, organization size, and verticalTo describe and forecast the Predictive Maintenance Market, in terms of value,by region—North America, Europe, Asia Pacific, Middle East & Africa and Latin AmericaTo provide detailed information regarding major factors influencing the market growth (drivers, restraints, opportunities, and challenges)To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contribution to the overall Predictive Maintenance MarketTo profile key players and comprehensively analyze their market positions in terms of ranking and core competencies2, along with detailing the competitive landscape for market leadersTo analyze competitive developments such as joint ventures, mergers and acquisitions, product developments, and ongoing research and development (R&D) in the Predictive Maintenance MarketTo provide the illustrative segmentation, analysis, and projection of the main regional marketsBrowse Adjacent Markets: Analytics Market Research Reports & Consulting
Related Reports:
Customer Data Platform Market – Global Forecast to 2028
Speech Analytics Market- Global Forecast to 2029
Text to Video AI Market – Global Forecast to 2027
Contact Center Analytics Market- Global Forecast to 2027
Procurement Analytics Market- Global Forecast to 2026
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Insight: https://www.marketsandmarkets.com/ResearchInsight/operational-predictive-maintenance-market.aspVisit Our Website: https://www.marketsandmarkets.com/Content Source:https://www.marketsandmarkets.com/PressReleases/operational-predictive-maintenance.asp
Logo: https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/predictive-maintenance-market-worth-47-8-billion-by-2029—exclusive-report-by-marketsandmarkets-302102534.html

Continue Reading

Artificial Intelligence

AeC Recognized by Frost & Sullivan for Leading the Customer Relationship Industry in Brazil

Published

on

aec-recognized-by-frost-&-sullivan-for-leading-the-customer-relationship-industry-in-brazil

AeC is the largest customer relationship company in Brazil and its reliable and customized customer care solutions help businesses create seamless end-user experiences.
SAN ANTONIO, March 29, 2024 /PRNewswire/ — Frost & Sullivan recently researched the customer experience outsourcing services industry and, based on its findings, recognizes AeC with the 2023 Company of the Year Award. AeC is connecting technology with outstanding customer service to increase efficiency and optimize the customer’s business journey. AeC leverages artificial intelligence (AI), data intelligence, machine learning (ML), natural language processing (NLP), fraud prevention, and real human experiences to guarantee an optimal customer experience (CX) in its clients’ business operations.

The company helps businesses deliver a remarkable CX to remain competitive in the marketplace and meet its clients’ demands. It consistently aims to enhance end-user CX by carefully analyzing customer data, testing new business models, and adjusting its processes based on customer feedback.
AeC drives its clients’ digital transformations with innovative tools that provide superior business process outsourcing (BPO) services. The company launched Vision, an advanced and intuitive solution that allows managers to track agents’ performance and deliver effective support. Moreover, its AeC HR technology platform, Robbyson, assists businesses by increasing engagement and efficiency with AI to automatically estimate, suggest, and forecast outcomes.
“With a legacy of BPO services leadership, the company’s compelling value proposition underpins its sustained success. AeC holds a solid position with a diversified client base, serving industry leaders of every market, including four of the top five Brazilian unicorns and two of the top five energy organizations in Brazil,” said Sebastian Menutti, industry principal at Frost & Sullivan.
With its customer-centric approach, the company provides consulting and highly customized projects for its clients. AeC bases its operations on the core principle that its success depends on customer satisfaction. For this reason, the company meets with clients at the pre-sales stage to identify their specific business requirements and challenges to develop tailor-made solutions.
“The company acknowledges that offering a complete product portfolio that aligns with broader market trends (e.g., omnichannel customer services, automation capabilities, and tools that address security challenges) is a key differentiator. Therefore, it constantly leverages technology to improve the efficiency and effectiveness of its services, such as automating processes and using data analytics to gain insights into end users’ behaviors and preferences,” noted Valentina Barcia, best practices research analyst at Frost & Sullivan.
Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Kristen MooreP: +1 (210) 247-3823E: [email protected]
About AeC
AeC is a Brazilian technology company specializing in customer relations. Leading by innovation, the most outstanding is the warm way of dealing with people and applying cutting-edge technology in its processes, such as artificial intelligence, cloud services, analytics, and automation tools. For over 30 years, it has developed customized consumer experience solutions in the market, helping companies in different segments, such as digital businesses, fintech, financial sector, telecommunications, services, retail, insurance, energy, and health. Currently, AeC has more than 43,000 employees and is certified by the Great Place to Work Institute (GPTW).
Photo – https://mma.prnewswire.com/media/2374892/Frost_and_Sullivan_AeC_Award_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/aec-recognized-by-frost–sullivan-for-leading-the-customer-relationship-industry-in-brazil-302103355.html

Continue Reading

Artificial Intelligence

Actuators Market worth $94.8 billion by 2029 – Exclusive Report by MarketsandMarkets™

Published

on

actuators-market-worth-$94.8-billion-by-2029-–-exclusive-report-by-marketsandmarkets™

CHICAGO, March 29, 2024 /PRNewswire/ — The Actuators market is estimated at USD 67.7 billion in 2024 and is projected to reach USD 94.8 billion by 2029, at a CAGR of 7.0 % from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth can be attributed to growing industrial automation and use of robots in various sectors like manufacturing and transportation, Developments in areas like sensor technology, connectivity, and control systems, The increasing demand for actuators is fueled by the expansion of sectors like healthcare (medical devices), oil & gas, and aerospace & defense, and the need for improved process control, energy efficiency, and safety regulations in various industries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=59465451
Browse in-depth TOC on “Actuators Market” 300 – Tables175 – Figures350 – Pages
Actuators Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 67.7 billion
Estimated Value by 2029
$ 94.8 billion
Growth Rate
Poised to grow at a CAGR of 7.0%
Market Size Available for
2019–2028
Forecast Period
2023–2028
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By Actuation, Application, Type, Vertical, and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Issues of leakage in pneumatic and hydraulic actuators
Key Market Opportunities
Increased spending on renewable sources of energy for power generation
Key Market Drivers
Rapid industrialization and utilization of robotics
The Electric segment held the largest growth rate in the Actuators market by actuation.
By actuation, the Actuators market has been segmented into electric, hydraulic, pneumatic, and others. electric Segment to hold the highest growth rate during the forecast period. Electrical actuators use electricity to produce motion. These actuators can be further classified into solenoid actuators and motor-driven actuators. A solenoid used in an electric actuator works on the principle of electromagnetism. Electrical actuators provide control and acceleration at higher speeds. The force for applying thrust can be managed without the requirement for compressed air and the related infrastructure, and hence the total energy consumption in these actuators is lower. Electrical actuators can be used for various applications where linear as well as rotary actuation is required. They can be used for low torque as well as high torque requirements.
The vehicle equipment segment is expected to account for the largest share of Actuators by application in 2024.
By application, the Actuators industry is segmented into industrial automation, robotics, and vehicle equipment. The vehicles and equipment segment includes actuators used in automotive, aircraft, ships, and defense vehicles. These can be either hydraulic, pneumatic, electrical, or mechanical actuators. Actuators are widely used in various systems and sub-systems of an automobile, aircraft, ships as well as defense vehicles.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=59465451
Asia Pacific accounts for the largest market share in 2024.
The Actuators market has been studied in North America, Europe, Asia Pacific, Middle East, and Rest of the World. The Asia Pacific region accounts for the largest market share in 2024 as well as throughout the forecast period due to the increasing demand for actuators in the region to enhance the growth of the market. India is expected to show the highest growth rate in Asia Pacific Region for Actuators market.
Major players operating in the Actuators companies are SMC Corporation (Japan), Rockwell Automation (US), Curtiss-wright Corporation (US), ABB Ltd (Switzerland), and Parker Hennifin Corporation (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=59465451
Browse Adjacent Market: Aerospace and Defence Market Research Reports & Consulting
Related Reports: 
Aircraft Sensors Market Size, Share & Growth Analysis Report by Aircraft Type (Fixed-wing, Rotary-wing, UAVs, AAM), Application (Engine, Aerostructures, Fuel & Hydraulic, Cabin), Sensor Type, End Use (OEM, Aftermarket), Connectivity (Wired, Wireless) and Geography- Global Forecast to 2027
Military Actuators Market by Application (Air, Land, Naval), System (Electrical, Hydraulic, Pneumatic, Mechanical), Component (Cylinders, Drives, Servo Valves, Manifolds), Type (Linear, Rotary), and Region (2019-2024)
Aircraft Actuators Market Size, Share & Industry Growth Analysis Report by Installation Type (OEM & Aftermarket), System, Technology (Hydraulic, Electric Hybrid, Mechanical, Pneumatic, and Full Electric), Type, Platform, Aircraft Type (Fixed Wing and Rotary Wing) and Region – Global Forecast to 2027
Aircraft Engine Market Size, Share & Industry Growth Analysis Report by Type (Turboprop, Turbofan, Turboshaft, Piston Engine), Platform (Fixed wing, Rotary Wing, UAV), Component (Compressor, Turbine, Gear Box, Exhaust Nozzle, Fuel System), Technology, and Global Growth Driver and Industry Forecast to 2026
Avionics Market by Platform (Military Aviation, Commercial Aviation, General Aviation, Special Mission Aviation), Fit, Systems and Region (North America, Europe, Asia Pacific, Middle East and Rest of the World) – Global Forecast to 2030
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Aashish MehraMarketsandMarkets™ INC. 630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/global-actuators-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/global-actuators.asp
Logo: https://mma.prnewswire.com/media/2297424/MarketsandMarkets_Logo.jpg  
 

View original content:https://www.prnewswire.co.uk/news-releases/actuators-market-worth-94-8-billion-by-2029—exclusive-report-by-marketsandmarkets-302102397.html

Continue Reading
Advertisement

Latest News

Trending